Okana Ventures Inc. Acquires North American Product Rights for...

FACTIVEA is an FDA-approved quinolone with 5-day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

http://www.biospace.com/news_story.aspx?StoryID=307220&full=1